Status:
RECRUITING
TERPS Trial for de Novo Oligometastic Prostate Cancer
Lead Sponsor:
University of Maryland, Baltimore
Conditions:
Prostate Cancer
Oligometastatic Disease
Eligibility:
MALE
18+ years
Phase:
PHASE2
Brief Summary
This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.
Detailed Description
This study will compare the effects, good and/or bad, of using the standard of care treatment (systemic therapy + primary prostate radiation) compared to standard of care treatment plus stereotactic a...
Eligibility Criteria
Inclusion
- Patient must have at least one and up to three asymptomatic metastatic tumor(s) of the bone or soft tissue (with at least one bone metastasis) develop within the past 6-months that are seen on imaging. Up to five lesions are allowed on advanced functional imaging such as fluciclovine (Axumin), choline or PSMA PET-CT scan.
- CT or MRI scan within 6 months of enrollment
- Bone scan within 6 months of enrollment
- Fluciclovine (Axumin), choline, or PSMA PET-CT scan within 6 months of enrollment (PET-CT scan is reasonable for study entry imaging as an alternative to CT/MRI scan and bone scan)
- Histologic confirmation of malignancy (primary or metastatic tumor).
- Patient may have had prior systemic therapy and/or ADT associated with treatment within 9-months of enrollment.
- PSA \> 0.5 but \<100.
- Patient must be ≥ 18 years of age.
- Patient must have a life expectancy ≥ 12 months.
- Patient must have an ECOG performance status ≤ 2.
- Patient must have the ability to understand and the willingness to sign a written informed consent document
Exclusion
- Castration-resistant prostate cancer (CRPC).
- Prior radiation therapy to an overlapping site of a target lesion that would preclude further radiation therapy
- Spinal cord compression or impending spinal cord compression.
- Suspected pulmonary and/or liver metastases (greater \>10 mm in largest axis).
- Patient receiving any other investigational agents.
- Inability to receive any form of systemic therapy in the opinion of a treating medical oncologist .
- Unable to lie flat during or tolerate PET/MRI, PET/CT or SABR.
- No radiographical evidence of cranial metastasis.
- Refusal to sign informed consent.
Key Trial Info
Start Date :
October 18 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 31 2027
Estimated Enrollment :
122 Patients enrolled
Trial Details
Trial ID
NCT05223803
Start Date
October 18 2022
End Date
July 31 2027
Last Update
November 7 2025
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
UC San Diego Moores Cancer Center
La Jolla, California, United States, 92093
2
Maryland Proton Treatment Center
Baltimore, Maryland, United States, 21201
3
UMMC
Baltimore, Maryland, United States, 21201
4
Upper Chesapeake Health
Bel Air, Maryland, United States, 21014